The GIPC1 antibody is a tool used to detect and study GIPC1 (GAIP-interacting protein C-terminus 1), a multifunctional adaptor protein involved in cellular signaling, trafficking, and receptor stabilization. GIPC1. part of the PDZ domain-containing protein family, interacts with diverse receptors and signaling molecules, including integrins, receptor tyrosine kinases (e.g., IGF-1R, VEGFR), and GPCRs, modulating pathways like PI3K/AKT and MAPK. It plays roles in cell adhesion, endocytosis, and apoptosis, with implications in cancer progression, metastasis, and drug resistance. Researchers use GIPC1 antibodies (polyclonal or monoclonal, often raised in rabbits or mice) in techniques such as Western blotting, immunohistochemistry, and immunofluorescence to assess protein expression, localization, and interactions in tissues or cell lines. Its overexpression in cancers (e.g., breast, pancreatic) has spurred interest in GIPC1 as a potential biomarker or therapeutic target. Antibody specificity is validated via knockdown controls or peptide blocking, ensuring reliability in experimental models. Ongoing studies explore its regulatory mechanisms in diseases, highlighting its dual roles in tumor suppression and promotion depending on context.